{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:05:11Z","timestamp":1780549511694,"version":"3.54.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"DOI":"10.1093\/oncolo\/oyag176","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T21:06:46Z","timestamp":1777842406000},"source":"Crossref","is-referenced-by-count":0,"title":["Withstanding the test of time for patients in oncology clinical trials"],"prefix":"10.1093","volume":"31","author":[{"given":"Katherine","family":"Zhuo","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington , Seattle, WA 98109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington , Seattle, WA 98109,","place":["United States"]},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center , Seattle, WA 98109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026060400321020300_oyag176-B1","doi-asserted-by":"publisher","first-page":"oyag096","DOI":"10.1093\/oncolo\/oyag096","article-title":"Planned time burden for patients participating in Phase 2 cancer trials","volume":"31","author":"Ouimet","year":"2026","journal-title":"Oncologist"},{"key":"2026060400321020300_oyag176-B2","doi-asserted-by":"publisher","first-page":"e678","DOI":"10.1200\/JOP.19.00328","article-title":"Opportunity costs of receiving palliative chemotherapy for metastatic pancreatic ductal adenocarcinoma","volume":"16","author":"Bange","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2026060400321020300_oyag176-B3","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1200\/OP.22.00737","article-title":"Evaluating the time toxicity of cancer treatment in the CCTG CO.17 trial","volume":"19","author":"Gupta","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"2026060400321020300_oyag176-B4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1200\/OP.24.00334","article-title":"Time burdens for participants with advanced cancer in phase I trials: a cross-sectional study","volume":"21","author":"Iskander","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"2026060400321020300_oyag176-B5","doi-asserted-by":"publisher","first-page":"102046","DOI":"10.1016\/j.esmoop.2023.102046","article-title":"Time toxicity associated with early phase clinical trial participation","volume":"8","author":"Nindra","year":"2023","journal-title":"ESMO Open"},{"key":"2026060400321020300_oyag176-B6","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/OP.23.00811","article-title":"Time toxicity experienced by early-phase cancer clinical trial participants","volume":"20","author":"Durbin","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"2026060400321020300_oyag176-B7","doi-asserted-by":"publisher","first-page":"e255033","DOI":"10.1001\/jamanetworkopen.2025.5033","article-title":"Health care contact days and outcomes in clinical trials vs routine care among patients with non-small cell lung cancer","volume":"8","author":"Gupta","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026060400321020300_oyag176-B8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00520-024-08487-2","article-title":"Reporting time toxicity in prospective cancer clinical trials: a scoping review","volume":"32","author":"Quinn","year":"2024","journal-title":"Support Care Cancer"},{"key":"2026060400321020300_oyag176-B9","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1080\/10428194.2024.2352086","article-title":"Mitigating time toxicity in lymphoma and multiple myeloma","volume":"65","author":"Di","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"2026060400321020300_oyag176-B10","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/oncolo\/oyae187","article-title":"Patients\u2019 considerations of time toxicity when assessing cancer treatments with marginal benefit","volume":"29","author":"Gupta","year":"2024","journal-title":"Oncologist"},{"key":"2026060400321020300_oyag176-B11","doi-asserted-by":"publisher","first-page":"OP2500898","DOI":"10.1200\/OP-25-00898","article-title":"Stakeholder perspectives on the term time toxicity to describe health care contact time associated with cancer treatments","volume":"12","author":"Stevens","year":"2026","journal-title":"JCO Oncol Pract"},{"key":"2026060400321020300_oyag176-B12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/hsw\/hlt001","article-title":"Unequal burden of disease, unequal participation in clinical trials: solutions from African American and Latino community members","volume":"38","author":"Ford","year":"2013","journal-title":"Health Soc Work"},{"key":"2026060400321020300_oyag176-B13","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1634\/theoncologist.2017-0628","article-title":"At what cost to clinical trial enrollment? A retrospective study of patient travel burden in cancer clinical trials","volume":"23","author":"Borno","year":"2018","journal-title":"Oncologist"},{"key":"2026060400321020300_oyag176-B14","doi-asserted-by":"publisher","first-page":"e2515205","DOI":"10.1001\/jamanetworkopen.2025.15205","article-title":"Clinical trial discussion and participation in a breast cancer cohort by race and ethnicity","volume":"8","author":"Chen","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026060400321020300_oyag176-B15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.trecan.2023.01.006","article-title":"The unequal burden of time toxicity","volume":"9","author":"Johnson","year":"2023","journal-title":"Trends Cancer"},{"key":"2026060400321020300_oyag176-B16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1200\/OP.20.01071","article-title":"Maximizing home time for persons with cancer","volume":"17","author":"Banerjee","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"2026060400321020300_oyag176-B17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1200\/JCO.22.00358","article-title":"Decentralized clinical trials in oncology: are we ready for a virtual-first paradigm?","volume":"41","author":"Fu","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026060400321020300_oyag176-B18","doi-asserted-by":"publisher","first-page":"e2447649","DOI":"10.1001\/jamanetworkopen.2024.47649","article-title":"Patient, caregiver, and clinician perspectives on the time burdens of cancer care","volume":"7","author":"Gupta","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026060400321020300_oyag176-B19","doi-asserted-by":"publisher","first-page":"e433648","DOI":"10.1200\/EDBK_433648","article-title":"Amplifying the patient\u2019s voice in oncology early-phase clinical trials: solutions to burdens and barriers","volume":"44","author":"Spencer","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026060400321020300_oyag176-B20","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jtct.2025.06.030","article-title":"Assessing quality of life and symptoms in transplantation and CAR-T recipients: expert panel recommendations from the Survivorship Special Interest Group of ASTCT","volume":"31","author":"Banerjee","year":"2025","journal-title":"Transplant Cell Ther"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag176\/68264395\/oyag176.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag176\/68264395\/oyag176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag176\/68264395\/oyag176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:33:26Z","timestamp":1780547606000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag176\/8675499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag176","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,7]]},"article-number":"oyag176"}}